Trending Stock News

Davidson D A & Company Has Boosted Its Hcp (HCP) Holding; Achillion Pharmaceuticals, Inc. (ACHN) Had 7 Analysts Last Week

Among 10 analysts covering Achillion Pharma (NASDAQ:ACHN), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Achillion Pharma had 24 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Buy” rating by Maxim Group on Thursday, February 25. The company was maintained on Monday, September 11 by Robert W. Baird. The firm has “Neutral” rating by Chardan Capital Markets given on Friday, November 4. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Buy” rating by Maxim Group on Wednesday, August 9. The stock has “Buy” rating by Maxim Group on Thursday, August 13. The firm has “Outperform” rating by Leerink Swann given on Thursday, May 18. As per Thursday, February 2, the company rating was initiated by Ladenburg Thalmann. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has “Sell” rating given on Friday, September 23 by Chardan Capital Markets. The firm has “Buy” rating by Leerink Swann given on Monday, December 11. The firm has “Market Perform” rating given on Wednesday, May 4 by Leerink Swann. See Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) latest ratings:

11/12/2017 Broker: Leerink Swann Rating: Buy New Target: $5.0 Maintain
23/10/2017 Broker: Robert W. Baird Rating: Hold New Target: $4.0 Maintain
11/09/2017 Broker: Robert W. Baird Rating: Hold New Target: $4.0 Maintain
11/08/2017 Broker: Leerink Swann Rating: Buy Maintain
10/08/2017 Broker: Robert W. Baird Old Rating: Outperform New Rating: Neutral Downgrade
09/08/2017 Broker: Maxim Group Rating: Buy New Target: $7.0000 Maintain
09/08/2017 Broker: Chardan Capital Markets Rating: Hold New Target: $4.0000 Maintain

Davidson D A & Company increased Hcp Inc (HCP) stake by 11.18% reported in 2017Q2 SEC filing. Davidson D A & Company acquired 10,321 shares as Hcp Inc (HCP)’s stock rose 2.09%. The Davidson D A & Company holds 102,639 shares with $3.28 million value, up from 92,318 last quarter. Hcp Inc now has $12.76 billion valuation. The stock decreased 0.63% or $0.17 during the last trading session, reaching $26.97. About 5.78M shares traded or 54.01% up from the average. HCP, Inc. (NYSE:HCP) has risen 8.01% since December 14, 2016 and is uptrending. It has underperformed by 8.69% the S&P500.

The stock increased 2.12% or $0.06 during the last trading session, reaching $2.89. About 6.65M shares traded or 248.89% up from the average. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 47.61% since December 14, 2016 and is downtrending. It has underperformed by 64.31% the S&P500.

Investors sentiment decreased to 0.96 in 2017 Q2. Its down 0.37, from 1.33 in 2017Q1. It worsened, as 8 investors sold Achillion Pharmaceuticals, Inc. shares while 37 reduced holdings. 21 funds opened positions while 39 raised stakes. 101.03 million shares or 4.27% more from 96.89 million shares in 2017Q1 were reported. Blackrock Incorporated owns 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 9.53M shares. South Dakota Council reported 843,500 shares stake. Ameritas Prtn holds 0% or 10,118 shares. Barclays Public Ltd Company reported 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Swiss Retail Bank reported 0% stake. Bvf Inc Il holds 2.49% or 3.49M shares in its portfolio. Amalgamated Natl Bank reported 14,410 shares. D E Shaw reported 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Millennium Mgmt Ltd Liability reported 0.02% stake. Cibc World Markets invested in 61,042 shares. Price T Rowe Associate Md has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 25,228 shares. Tiaa Cref Management Lc reported 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). New York State Common Retirement Fund reported 118,300 shares. Gemmer Asset Mngmt Ltd Limited Liability Company owns 200 shares or 0% of their US portfolio. Invesco holds 0% or 90,441 shares.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $398.41 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

Investors sentiment decreased to 0.85 in 2017 Q2. Its down 0.38, from 1.23 in 2017Q1. It turned negative, as 35 investors sold HCP shares while 170 reduced holdings. 63 funds opened positions while 190 raised stakes. 411.39 million shares or 1.65% more from 404.71 million shares in 2017Q1 were reported. United Ser Automobile Association holds 0.01% or 146,957 shares in its portfolio. Conning accumulated 30,296 shares. Rmsincerbeaux Capital Mgmt Llc has 0.53% invested in HCP, Inc. (NYSE:HCP) for 18,544 shares. 1,500 were accumulated by Nelson Van Denburg & Campbell Wealth Management Gru Ltd Liability Corporation. Ronna Sue Cohen invested in 58,581 shares. Arkansas-based Stephens Ar has invested 0.05% in HCP, Inc. (NYSE:HCP). Brown Advisory Lc accumulated 7,755 shares or 0.06% of the stock. Dimensional Fund Advsrs LP accumulated 6.54M shares. Connecticut-based Essex Services has invested 0.07% in HCP, Inc. (NYSE:HCP). Genesee Valley owns 0.09% invested in HCP, Inc. (NYSE:HCP) for 6,385 shares. Sarasin Partners Ltd Liability Partnership holds 0.02% or 28,477 shares in its portfolio. 379,455 were reported by Nomura Asset Mngmt Limited. State Of New Jersey Common Pension Fund D, New Jersey-based fund reported 87,000 shares. Cahill Financial Advsr invested 0.14% of its portfolio in HCP, Inc. (NYSE:HCP). Panagora Asset Management holds 0.01% in HCP, Inc. (NYSE:HCP) or 59,515 shares.

Among 19 analysts covering HCP (NYSE:HCP), 3 have Buy rating, 1 Sell and 15 Hold. Therefore 16% are positive. HCP had 64 analyst reports since September 8, 2015 according to SRatingsIntel. BMO Capital Markets maintained HCP, Inc. (NYSE:HCP) rating on Monday, September 4. BMO Capital Markets has “Hold” rating and $32.0 target. The rating was maintained by Jefferies with “Hold” on Monday, May 15. The firm has “Underweight” rating given on Wednesday, January 6 by Barclays Capital. Citigroup maintained HCP, Inc. (NYSE:HCP) rating on Wednesday, August 24. Citigroup has “Neutral” rating and $38 target. The firm has “Sell” rating given on Monday, September 21 by Goldman Sachs. The company was maintained on Friday, November 6 by RBC Capital Markets. Stifel Nicolaus maintained it with “Hold” rating and $30.0 target in Sunday, August 20 report. The rating was maintained by KeyBanc Capital Markets with “Hold” on Friday, September 15. The firm has “Underperform” rating given on Tuesday, July 26 by Raymond James. The stock of HCP, Inc. (NYSE:HCP) has “Hold” rating given on Monday, August 7 by RBC Capital Markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *